Denosumab in multiple myeloma patients with severe renal impairment: a multicenter phase 2 study - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

A Multicenter Phase 2 Study of Denosumab for Multiple Myeloma Patients With Severe Renal Impairment

  • By

  • Elizabeth K. O’Donnell

  • Omar Nadeem

  • Jacob P. Laubach

  • Giada Bianchi

  • Andrew R. Branagan

  • Brea C. Lipe

  • Paul G. Richardson

  • Ehsan Malek

  • Robb S. Friedman

  • Ajay K. Nooka

  • Robert Redd

  • Noopur S. Raje

  • Andrew J. Yee

  • November 2, 2026

Share

  • 1

    This prospective, multicenter phase 2 trial evaluated denosumab in adults with multiple myeloma and creatinine clearance below 30 mL/min who were ineligible for bisphosphonates.

  • 2

    Of 24 enrolled patients, 22 received denosumab; median creatinine clearance was 23.8 mL/min, and 9 patients (41%) were receiving dialysis.

  • 3

    At 3 months, median serum CTX decreased 73% from baseline (n = 18; P = .0002), and 1-year skeletal-related event-free survival was 85.4%.

  • 4

    Hypocalcemia occurred in 77.3% of patients, was grade 3 or higher in 31.8%, and required intravenous calcium in 4 patients despite calcium and vitamin D supplementation.

  • 5

    The study closed early because of slow accrual and was limited by its small sample size and inclusion of patients with newly diagnosed and relapsed disease.

Original Source(s)

Denosumab in multiple myeloma patients with severe renal impairment: a multicenter phase 2 study

  • by Elizabeth K. O’Donnell, Omar Nadeem, Jacob P. Laubach, Giada Bianchi, Andrew R. Branagan, Brea C. Lipe, Paul G. Richardson, Ehsan Malek, Robb S. Friedman, Ajay K. Nooka, Robert Redd, Noopur S. Raje, Andrew J. Yee

  • November 2, 2026

Related Content

Correction: Evaluation of the Applicability of Synthetic Data in the Development of Colorectal Cancer Survival Prediction Models: External Validation of Advanced Machine Learning Models Based on National Cancer Data Center Data

Risk-Based Lung Cancer Screening for People Who Never Smoked

Increased Risk of Subsequent Cancers in Patients With Sézary Syndrome